Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Post-Transplant Events

Safety of low-dose low-molecular-weight-heparins in thrombocytopenic stem cell transplantation patients: a case series and review of the literature

Bone Marrow Transplantation volume 35, pages 1071–1077 (2005)Cite this article

Summary:

Few attempts have been made to examine the feasibility of safely administering low-molecular-weight-heparins (LMWHs) in the presence of concurrent thrombocytopenia. We retrospectively investigated the safety of low-dose LMWH in BMT patients, a population at risk of bleeding. In total, 26 patients received at least one dose of low-dose enoxaparin (ie <1 mg/kg/day) during thrombocytopenia. s.c. enoxaparin 40 mg once daily was given in 85% of the cohort. The mean number of platelet days <55 × 109 and <20 × 109/l were 16.5 days (95% CI=8.04–24.96) and 4.14 days (95% CI=2.35–5.93), respectively. The mean number of low-dose enoxaparin administration days when platelet <55 × 109 and 20 × 109/l were 9.89 days (95% CI=3.26–16.53) and 2.25 days (95% CI=0.57–3.93), respectively. Minor bleeding occurred in four patients (15%) whereas major episodes developed in two patients (8%). The latter two events occurred during the transition between full therapeutic (ie 1.5–2 mg/kg/day) and low-dose enoxaparin close to the onset of thrombocytopenia. The present case series, along with the discussed literature, descriptively suggests that low-dose enoxaparin may be safely administered at a platelet count in the range of 20 and 55 × 109/l in BMT patients who weigh >55 kg.

This is a preview of subscription content, access via your institution

Access options

Similar content being viewed by others

References

  1. Bacigalupo A . Haemopoietic stem cell transplantation: the impact of hemorrhagic complications. Blood Rev 2003; 17: S6–S10.

    Article  PubMed  Google Scholar 

  2. Gordon B, Tarantolo S, Ruby E et al. Increased platelet transfusion requirement is associated with multiple organ dysfunctions in patients undergoing hematopoietic stem cell transplantation. Bone Marrow Transplant 1998; 22: 999–1003.

    Article  CAS  PubMed  Google Scholar 

  3. Dominietto A, Raiola AM, Van Lint MT et al. Factors influencing hematologic recovery after allogeneic hematopoietic stem cells transplant: graft-versus-host disease, donor type, cytomegalovirus infections and cell dose. Br J Haematol 2001; 112: 219–227.

    Article  CAS  PubMed  Google Scholar 

  4. Zumberg MS, Rosario MU, Nejame CF et al. a prospective randomized trial of prophylactic platelet transfusion and bleeding incidence in hematopoietic stem cell transplant recipients: 10 000/μl vs 20 000/μl trigger. Biol Bone Marrow Transplant 2002; 8: 569–576.

    Article  Google Scholar 

  5. Sutherland DE, Weitz IC, Liebman HA . Thrombotic complications of cancer: epidemiology, pathogenesis, diagnosis, and treatment. Am J Hematol 2003; 72: 43–52.

    Article  PubMed  Google Scholar 

  6. Goldenberg N, Kahn SR, Solymoss S . Markers of coagulation and angiogenesis in cancer-associated venous thromboembolism. J Clin Oncol 2003; 21: 4194–4199.

    Article  CAS  PubMed  Google Scholar 

  7. Mandala M, Ferretti G, Cremonesi M et al. Venous thrombolism and cancer: new issues for an old topic. Crit Rev Oncol Hematol 2003; 48: 65–80.

    Article  PubMed  Google Scholar 

  8. Caine GJ, Stonelake PS, Rea D, Lip GH . Coagulation complications in breast cancer. Cancer 2003; 98: 1578–1586.

    Article  PubMed  Google Scholar 

  9. Zangari M, Anaissie E, Barlogie B et al. Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy. Blood 2001; 98: 1614–1615.

    Article  CAS  PubMed  Google Scholar 

  10. Amato RJ . Thalidomide therapy for renal carcinoma. Crit Rev Oncol Hematol 2003; 46: S59–S65.

    Article  PubMed  Google Scholar 

  11. Tallman MS, Andersen JW, Schiffer CA et al. A prospective randomized study of ATRA induction and maintenance therapy or patients with acute promyelocytic leukemia. N Engl J Med 1997; 337: 1021–1028.

    Article  CAS  PubMed  Google Scholar 

  12. Fijnheer R, Paijmans B, Verdonck LF et al. Factor V Leiden in central venous catheter-associated thrombosis. Br J Haematol 2002; 118: 267–270.

    Article  CAS  PubMed  Google Scholar 

  13. Stephens LC, Haire WD, Schmit-Pokorny K et al. Granulocyte macrophage colony stimulating factor: high incidence of apheresis catheter thrombosis during peripheral stem cell collection. Bone Marrow Transplant 1993; 11: 51–54.

    CAS  PubMed  Google Scholar 

  14. Verso M, Agnelli G . Venous thromboembolism associated with long-term use of central venous catheters in cancer patients. J Clin Oncol 2003; 21: 3665–3675.

    Article  PubMed  Google Scholar 

  15. Klerk CPW, Smorenburg SM, Buller HR . Thrombosis prophylaxis in patient populations with a central venous catheter. Arch Intern Med 2003; 163: 1913–1921.

    Article  PubMed  Google Scholar 

  16. Walshe LJ, Malak SF, Eagan J, Sepkowitz KA . Complications rates among cancer patients with peripherally inserted central catheters. J Clin Oncol 2002; 20: 3276–3281.

    Article  PubMed  Google Scholar 

  17. Sletnes KE, Holte H, Halvorsen S et al. Activation of coagulation and deep venous thrombosis after bone marrow harvesting and insertion of a Hickman-catheter in ABMT patients with malignant lymphoma. Bone Marrow Transplant 1996; 17: 577–581.

    CAS  PubMed  Google Scholar 

  18. Conlan MG, Haire WD, Lieberman RP et al. Catheter-related thrombosis in patients with refractory lymphoma undergoing autologous stem cell transplantation. Bone Marrow Transplant 1991; 7: 235–240.

    CAS  PubMed  Google Scholar 

  19. Ibrahim RB, Peres E, Dansey R et al. Antithrombin-III in the management of hematopoietic-stem-cell transplantation-associated toxicity. Ann Pharmacother 2004; 38: 1053–1059.

    Article  CAS  PubMed  Google Scholar 

  20. Lee AY . Epidemiology and management of venous thromboembolism in patients with cancer. Thromb Res 2003; 110: 167–172.

    Article  CAS  PubMed  Google Scholar 

  21. Ibrahim RB, Stroempl LE, Abella EM, Racine E . Enoxaparin safety in patients with severe thrombocytopenia. Ann Pharmacother 2002; 36: 1478–1479 (letter).

    PubMed  Google Scholar 

  22. Lee AY, Levine MN, Baker RI et al. Low-molecular-weight heparin vs a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 2003; 349: 146–153.

    Article  CAS  PubMed  Google Scholar 

  23. Savage KJ, Wells PS, Schulz V et al. Outpatient use of low molecular weight heparin (dalteparin) for the treatment of deep vein thrombosis in the upper extremity. Thromb Haemost 1999; 82: 1008–1010.

    Article  CAS  PubMed  Google Scholar 

  24. Kakkar AK, Levine MN, Kadziola Z et al. Low molecular weight heparin therapy with dalteparin and survival in advanced cancer: the fragmin advanced malignancy outcome study (FAMOUS). J Clin Oncol 2004; 22: 1944–1948.

    Article  CAS  PubMed  Google Scholar 

  25. Lagro SWJ, Verdonck LF, Rinkes BI, Dekker AW . No effect of nadroparin prophylaxis in the prevention of central venous catheter-associated thrombosis in bone marrow transplant recipients. Bone Marrow Transplant 2000; 26: 1103–1106.

    Article  CAS  PubMed  Google Scholar 

  26. Monreal M, Alastrue A, Rull M et al. Upper extremity deep venous thrombosis in cancer patients with venous access devices-prophylaxis with low molecular weight heparin (Fragmin). Thromb Haemost 1996; 75: 251–253.

    CAS  PubMed  Google Scholar 

  27. Boraks P, Seale J, Price P et al. Prevention of central venous catheter associated thrombosis using minidose warfarin in patients with hematological malignancies. Br J Haematol 1998; 101: 483–486.

    Article  CAS  PubMed  Google Scholar 

  28. Bern M, Lokich J, Wallach S et al. Very low doses of warfarin can prevent thrombosis in central venous catheters. A randomized prospective trial. Ann Intern Med 1990; 112: 423–428.

    Article  CAS  PubMed  Google Scholar 

  29. Levine M, Hirsh J, Gent M et al. Double-blind randomized trial of very low-dose-warfarin for prevention of thromboembolism in stage IV breast cancer. Lancet 1994; 343: 886–889.

    Article  CAS  PubMed  Google Scholar 

  30. Prandoni P, Lensing AW, Piccioli A et al. Reccurent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood 2002; 100: 3484–3488.

    Article  CAS  PubMed  Google Scholar 

  31. Couban S, Goodyear M, Burnell M et al. A randomized double blind placebo-controlled study of low dose warfarin for the prevention of symptomatic central venous catheter-associated thrombosis in patients with cancer. Blood 2002; 100: 703a (abstr 2769).

    Article  Google Scholar 

  32. Simon M, Hahn T, Ford LA et al. Retrospective multivariate analysis of hepatic veno-occlusive disease after blood or marrow transplantation: possible beneficial use of low molecular weight heparin. Bone Marrow Transplant 2001; 27: 627–633.

    Article  CAS  PubMed  Google Scholar 

  33. Drakos PE, Nagler A, Or R et al. Low-molecular-weight heparin for Hickman catheter-induced thrombosis in thrombocytopenic patients undergoing bone marrow transplantation. Cancer 1992; 70: 1895–1898.

    Article  CAS  PubMed  Google Scholar 

  34. Or R, Nagler A, Shpilberg O et al. Low-molecular-weight heparin for the prevention of veno-occlusive disease of the liver in bone marrow transplantation patients. Transplantation 1996; 7: 1067–1071.

    Article  Google Scholar 

  35. Forrest DL, Thompson K, Dorcas VG et al. Low molecular weight heparin for the prevention of hepatic veno-occlusive disease after hematopoietic stem cell transplantation: a prospective phase II study. Bone Marrow Transplant 2003; 31: 1143–1149.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  36. Schimdt F, Faul C, Dichgans J, Weller M . Low molecular weight heparin for deep vein thrombosis in glioma patients. J Neurol 2002; 249: 1409–1412.

    Article  Google Scholar 

  37. Sakuragawa N, Hasegawa H, Maki M et al. Clinical evaluation of low-molecular-weight heparin on disseminated intravascular coagulation. Thromb Res 1993; 72: 475–500.

    Article  CAS  PubMed  Google Scholar 

  38. Majumdar G . Idiopathic chronic DIC controlled with low-molecular-weight heparin. Blood Coagul Fribrinolysis 1996; 7: 97–98.

    Article  CAS  Google Scholar 

  39. Massicotte P, Julina J, Gent M et al. An open-level randomized trial of the low molecular weight heparin for the prevention of central venous line-related thrombotic complications in children; the PROTEKT trial. Thromb Res 2003; 19: 101–108.

    Article  Google Scholar 

  40. Or R, Elad S, Shpilberg O, Eldor A . Low molecular weight heparin stimulates megakaryocytopoiesis in bone marrow transplantation patients. Am J Hematol 1996; 53: 46–58.

    Article  CAS  PubMed  Google Scholar 

  41. Shen ZX, Basara N, Xi XD et al. Fraxiparin, a low-molecular-weight heparin, stimulated megakaryocytopoiesis in vitro and in vivo in mice. Br J Haematol 1994; 88: 608–612.

    Article  CAS  PubMed  Google Scholar 

  42. Caen J, Bellucci S . Faut-il prescrire l’heparine pour faire remonter le chiffre laquettaire? Sang Thrombose Vaisseaux 1996; 8: 125–127.

    Google Scholar 

  43. Nieuwenhuis HK, Sixma JJ . Treatment of disseminated intravascular coagulation in acute promyelocytic leukemia with low-molecular-weight heparinoid Org 10172. Cancer 1986; 58: 761–764.

    Article  CAS  PubMed  Google Scholar 

  44. Breddin HK . Prophylaxis and treatment of deep venous thrombosis. Semin Thromb Hemost 2000; 26 (Suppl. 1): 47–52.

    Article  CAS  PubMed  Google Scholar 

  45. Porras MC, Martin M, Ruiz M . Dalteparin-induced retroperitoneal bleeding. Ann Pharmacother 2001; 35: 261–262 (letter).

    Article  Google Scholar 

  46. Melde S . Enoxaparin-induced retroperitoneal hematoma. Ann Pharmacother 2003; 37: 822–824.

    Article  PubMed  Google Scholar 

  47. Montoya JP, Pokala N . Retroperitoneal hematoma and enoxaparin. Ann Intern Med 1999; 131: 796–797.

    Article  CAS  PubMed  Google Scholar 

  48. Dabney A, Bastani B . Enoxaparin-associated severe retroperitoneal bleeding and abdominal compartment syndrome: a report of two cases. Intensive Care Med 2001; 27: 1954–1957.

    Article  CAS  PubMed  Google Scholar 

  49. Chan-Tack KM . Fatal spontaneous retroperitoneal hematoma secondary to enoxaparin. South Med J 2003; 96: 58–60.

    Article  PubMed  Google Scholar 

  50. Hirsh J, Raschke R . Heparin and low-molecular-weight heparin: the seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest 2004; 126: 188S–203S.

    Article  CAS  PubMed  Google Scholar 

  51. Duplaga BA, Rivers CW, Nutescu E . Dosing and monitoring of low-molecular-weight heparins in special populations. Pharmacotherapy 2001; 21: 218–234.

    Article  CAS  PubMed  Google Scholar 

  52. Nieuwenhuis HK, Albada J, Banga JD, Sixma JJ . Identification of risk factors for bleeding during treatment of acute venous thromboembolism with heparin or low-molecular weight heparins. Blood 1991; 78: 2337–2343.

    CAS  PubMed  Google Scholar 

  53. Rebulla P, Finazzi G, Marangoni F et al. The threshold for prophylactic platelet transfusions in adults with acute myeloid leukemia. N Engl J Med 1997; 337: 1870–1875.

    Article  CAS  PubMed  Google Scholar 

  54. Gil-Fernandez JJ, Alegre A, Fernandez-Villalta MJ et al. Clinical results of a stringent policy on prophylactic platelet transfusion: non-randomized comparative analysis in 190 bone marrow transplant patients from a single institution. Bone Marrow Transplant 1996; 18: 931–935.

    CAS  PubMed  Google Scholar 

  55. Nevo S, Enger C, Hartley E et al. Acute bleeding and thrombocytopenia after bone marrow transplantation. Bone Marrow Transplant 2001; 27: 65–72.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

Natalie A Dieterle, PA-C and Jennifer Kozlowski, NP for their valuable editorial review of the manuscript. The study was partially supported by an NCI Cancer Center Support Grant, CA-22453.

Author information

Authors and Affiliations

  1. Department of Pharmacy, Karmanos Cancer Institute/Harper University Hospital/The Detroit Medical Center, Detroit, MI, USA

    R B Ibrahim, M M Gumma & N Milan

  2. Eugene Applebaum College of Pharmacy and Allied Health Professions, Wayne State University, 3990 John R, Detroit, MI, USA

    R B Ibrahim

  3. Bone Marrow Transplantation Service, Karmanos Cancer Institute, School of Medicine, Wayne State University, Detroit, MI, USA

    E Peres, R Dansey, M H Abidi, E M Abella & J Klein

  4. Biostatistics Core, Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, MI, USA

    D W Smith & L K Heilbrun

Authors
  1. R B Ibrahim
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. E Peres
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. R Dansey
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. M H Abidi
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. E M Abella
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. M M Gumma
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. N Milan
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. D W Smith
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. L K Heilbrun
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. J Klein
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to R B Ibrahim.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ibrahim, R., Peres, E., Dansey, R. et al. Safety of low-dose low-molecular-weight-heparins in thrombocytopenic stem cell transplantation patients: a case series and review of the literature. Bone Marrow Transplant 35, 1071–1077 (2005). https://doi.org/10.1038/sj.bmt.1704952

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.bmt.1704952

Keywords

This article is cited by

Search

Advanced search

Quick links